Diversion and Abuse of Buprenorphine

APPENDIX A
FEDERAL AND STATE OFFICIALS CONSULTED FOR THE ASSESSMENT
_________________________________________________________________
The active participation and many contributions of the following State and Federal officials are
acknowledged with gratitude:
• Anton C. Bizzell, M.D., Medical Director, Division of Pharmacologic Therapies, Center
for Substance Abuse Treatment/SAMHSA
• Eric Buel, Vermont Department of Public Safety
• Barbara Cimaglio, Director, Division of Alcohol & Drug Abuse Programs, Vermont
Department of Health
• Gretchen Feussner, Office of Diversion Control, U.S. Drug Enforcement Administration
• June Howard, Office of Diversion Control, U.S. Drug Enforcement Administration
• Raymond D. Hylton, Jr., R.N., M.S.N., Lead Public Health Advisor, Division of
Pharmacologic Therapies, Center for Substance Abuse Treatment/SAMHSA
• Peter Lee, Chief of Treatment, Division of Alcohol & Drug Abuse Programs, Vermont
Department of Health
• Robert Lubran, M.S., M.P.A., Director, Division of Pharmacologic Therapies, Center for
Substance Abuse Treatment/SAMHSA
• Todd Mandell, M.D., Medical Director, Division of Alcohol & Drug Abuse Programs,
Vermont Department of Health
• Linda Piasecki, Division of Alcohol & Drug Abuse Programs, Vermont Department of
Health
• Nicholas Reuter, M.P.H., Team Leader, Certification & Waiver Team, Division of
Pharmacologic Therapies, Center for Substance Abuse Treatment/SAMHSA
• Karen Simeon, Northern New England Poison Control Center
• Arlene Stanton, Ph.D., Team Leader, Buprenorphine Assessment Project, Division of
Pharmacologic Therapies, Center for Substance Abuse Treatment/SAMHSA
• Scott Strenio, M.D., Medical Director, Office of Vermont Health Care Access
Buprenorphine Assessment: Final Report 23